New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment

In a recent article published in Clinical Microbiology and Infection, researchers reviewed all registered trials currently investigating potential treatment options for post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS).

Long COVID and its Management

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study

Frontiers Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial - The Lancet Respiratory Medicine

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 - eClinicalMedicine

Trauma Care, Free Full-Text

Understanding the Post COVID-19 Condition (Long COVID) in Adults and the Expected Burden for Ontario - Ontario COVID-19 Science Advisory Table

Two Years into the COVID-19 Pandemic: Lessons Learned